Top Companies in Gene Synthesis Market in 3 Minutes What You Want
Global Gene Synthesis Market is valued at USD 2.16 Billion in 2021 and is projected to attain a value of USD 6.58 Billion by 2028
Market Overview:
According to vantage market research, the Global Gene Synthesis Market is valued at USD 2.16 Billion in 2021 and is projected to attain a value of USD 6.58 Billion by 2028 at a CAGR of 17.9% during the forecast period, 2022–2028. The rise in the adoption of gene therapy has improved the need for rapid gene synthesis products which are error-free gene sequences obtained in less time and thus act as a driver for the gene synthesis market. The increasing demand for personalized medication manufacturing has paved the path for genomic demands thereby being a conceivable benefit in the market and impacting the overall market size, hence acting as a driver for the gene synthesis market growth.
As personalized medication aims to deliver customized therapies to particular patients, relying on the molecular basis of disease, and become favored in recent years. Healthcare technology, genomics, connected appliances, big data analytics, and artificial intelligence are developing due to the developing gene synthesis. This is allowing medical providers to deliver better diagnoses, and make better treatment decisions. Therefore, acting as a driving factor for the gene synthesis market.
Following are the Top 7 leading Companies in Gene Synthesis Market:
Company Name |
Revenue in USD |
· GenScript |
$798 Million |
· Brooks Automation, Inc. |
$513.7 Million |
· Boster Biological Technology |
<$5 Million |
· Twist Bioscience |
$90 Million |
· ProteoGenix |
<$5 Million |
· Biomatik |
<$5 Million |
· ProMab Biotechnologies, Inc. |
$8 Million |
GenScript was founded in New Jersey; United States in 2002, the company is a well-recognised biotechnology company. Based on proprietary gene synthesis technology and the other technology and know-hows on life-science research and application, the company has four well established major platforms including (i) a leading life-science services and products platform to provide one-stop solutions to global research communities, (ii) a biologics contract development and manufacturing organization (the "CDMO") platform, (iii) an industrial synthetic products platform, and (iv) an integrated global cell therapy platform.
Brooks Automation was founded in 1978 and is based in Chelmsford, Massachusetts. The company is a provider of automation, vacuum and instrumentation equipment for multiple markets, including semiconductor manufacturing, technology device manufacturing, and life sciences. The company provides mainly four kinds: semiconductor automation and life science systems equipment, gas analysis and vacuum measurement, cryopumps, cryochillersand compressors, asset tracking equipment. The company features in developing and building the handling system and related technology. Automation products are used to support both atmospheric and vacuum based processes while the company's focus remains on improving performance and productivity. The company provides vacuum pumps and instrumentation to maintain pressure consistency of the known process gas. The Brooks Life Science Systems provides automated sample management systems and equipment, such as automated blood fractionation equipment, cellular imaging, and consumables parts.
Boster Biological Technology was founded in 1993, the company is an antibody manufacturer specializing in high-sensitivity, high-specificity ELISA kits and WB/IHC compatible antibodies. The company has spent the last two and half decades perfecting there techniques and technology, and there products have been well-cited in over 29,000 publications. There antibodies are thoroughly validated for IHC, WB, ELISA, and Flow Cytometry. The company strives to provide the best service and have earned the trust of researchers worldwide. The antibodies are tested with real tissues to ensure enough affinity with endogenous level of target proteins. In addition, they also validate antibodies in a quantitative fashion by testing them on known quantities of recombinant proteins so that you know what to expect if there is 1ng, 2.5ng or 5ng of the target protein in the sample.
Twist Bioscience was founded in 2013, the company is a public company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. The company works in providing engaging service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, the customers are developing ways to better lives and improve the sustainability of the planet. The company have created a revolutionary silicon platform that offers precision at a scale unavailable anywhere else.
ProteoGenix is a leading therapeutic antibody development service provider. In 2003, ProteoGenix was started with the idea of developing diagnostic assays and bio therapeutics to target proteins discovered by its founders. The management quickly understood the incredible value of high quality antibodies and proteins for developing biopharma products and subsequently gaining access to the difficult-to-reach clinic setting.The company's idea of sharing its experience in therapeutic antibodies and custom assays with the life science community quickly gained ground. The company's main objective is to anticipate future requirements of biomolecules from the very beginning and to subsequently design a suitable development strategy. This means providing an extensive range of innovative solutions and technologies.
Biomatik primarily focused on Biochemical, Enzymes, Gene Synthesis, and Peptide Synthesis services in the early years, but has since rapidly expanded its offerings to include ELISA Kits, Protein Production, Antibody Production, and Antibody Sequencing Services. The company works closely with their partners at the R&D and production levels, along with 35+ distributors in the world. The company's goal is to provide worldwide researchers with quality research products and customized solutions at affordable prices to be a truly valuable partner in life sciences research and drug discovery.
ProMab Biotechnologies, Inc. was founded in 2001, the company develops and commercializes recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology, and immunology, using novel high-throughput technologies. The company provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies. The company is the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies.
Get Free Sample Here: https://www.vantagemarketresearch.com/gene-synthesis-market-1259/request-sample
For More Information about each of these companies. Vantage Market Research Report comes up with detail analysis of each major player in the industry. The Study provides Global market size & share, Emerging trends, In-depth analysis of key players, Development opportunities, Sales, Revenue Forecast.